CN1706473A - Anticancer taxad Chinese medicine prepn - Google Patents
Anticancer taxad Chinese medicine prepn Download PDFInfo
- Publication number
- CN1706473A CN1706473A CN 200510049853 CN200510049853A CN1706473A CN 1706473 A CN1706473 A CN 1706473A CN 200510049853 CN200510049853 CN 200510049853 CN 200510049853 A CN200510049853 A CN 200510049853A CN 1706473 A CN1706473 A CN 1706473A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- ramulus
- anticancer
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is anticancer taxad Chinese medicine preparation and the Chinese medicine preparation is prepared with taxad, gynostemma pentaphylla, astragalus root, ophiopogon root, figwort and other seven kinds of Chinese medicinal materials in certain weight proportion. The Chinese medicine preparation is developed based on traditional Chinese medical and pharmacological theory, especially strengthening body's resistance and eliminating evil, and invigorating vital energy Yin, to resist cancer and detoxicate. It has high anticancer and detoxication effect and less toxic side effect, and is suitable for the auxiliary treatment of tumors, especially of patient after surgical operation, radiotherapy and chemotherapy.
Description
Technical field
The present invention relates to a kind of Chinese medicine medicine for preventing preparation, especially relate to a kind of anticancer taxad Chinese medicine preparation.
Background technology
Ramulus et folium taxi cuspidatae is commonly called as " Ramulus et folium taxi cuspidatae " at folks of china, early on the books in the classical Compendium of Material Medica of motherland's medical science, be mainly used in treatment cholera, typhoid fever and be used for toxin expelling, and modern Chinese medicine is also used it for treatment diabetes, nephropathy and some gynaecopathias.From the American successfully extracted " paclitaxel " in 1971 from Ramulus et folium taxi cuspidatae after, people find through years of researches, compositions such as the contained paclitaxel of Ramulus et folium taxi cuspidatae, taxol, baccatin III have the broad spectrum anticancer effect, this effect is by acting on microtubule/tubulin system, promote that micro protein is assembled into microtubule, and suppress the depolymerization of microtubule, thereby it is unusual to cause the tumor cell microtubule to be arranged, spindle loses normal function, causes cell death.At present, these extracts of Ramulus et folium taxi cuspidatae have been widely used in the clinical treatment of cancer, but the Chinese herbal medicine that is directly used in the treatment cancer is also considerably less, a kind of anticancer health-care Chinese yew combination was disclosed in the disclosed 01129759.X Chinese invention patent application specification on May 1st, 2002, with the taxus wood tissue is primary raw material, the root that comprises the Semen Phaseoli Lignum seu Ramulus Cunninghamiae Lanceolatae, stem, leaf, do powder or granule with bark, the composition of each compositions and weight percentage are taxus wood tissue 50% ~ 97%, additive is 3%～50%, additive is a Herba Hedyotidis Diffusae, the mixture of any one or its two arbitrary proportion of Rabdosia rubescens, with taxus wood tissue through pulverizing, dry also sterilization, and fully mix in proportion with the powder of additive, can brew with boiled water and drink or make various beverages and drink, have certain anticancer effect.But people show through years of researches, when Ramulus et folium taxi cuspidatae is used as Chinese herbal medicine, because content of taxol is small, affect the treatment, and Ramulus et folium taxi cuspidatae has certain toxic and side effects, and are especially more common to gastral stimulation, damage and allergic rash.
Summary of the invention
Technical problem to be solved by this invention be provide at above-mentioned prior art present situation a kind of curative effect comparatively significantly, the less anticancer taxad Chinese medicine preparation of toxic and side effects.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: a kind of anticancer taxad medicine, it is by following component
Make: (consumption is a weight portion)
Ramulus et folium taxi cuspidatae 6～8 ginseng medicines 0.5～1 Herb Gynostemmae Pentaphylli 2～4 Dendrobium medicines 0.5～1
The Radix Astragali 4～6 Radix Scrophulariaes, 1.5～3 Fructus Lycii 4～6,4～6 Radix Ophiopogonis
Semen Coicis 4～6 Radix Glycyrrhizaes 1～2 Fructus Crataegi 4～6 Fructus Jujubaes 4～6.
Medicine of the present invention can be made by following component: (consumption is a weight portion)
Ramulus et folium taxi cuspidatae 6～8 Radix Panacis Quinquefoliis 0.5～1 Herb Gynostemmae Pentaphylli 2～4 Herba Dendrobii 0.5～1
The Radix Astragali 4～6 Radix Scrophulariaes, 1.5～3 Fructus Lycii 4～6,4～6 Radix Ophiopogonis
Semen Coicis 4～6 Radix Glycyrrhizaes 1～2 Fructus Crataegi 4～6 Fructus Jujubaes 4～6.
Medicine optimum weight of the present invention (part) proportioning is:
Ramulus et folium taxi cuspidatae 8 Radix Panacis Quinquefoliis 1 Herb Gynostemmae Pentaphylli 4 Herba Dendrobii 1
The Radix Astragali 6 Radix Scrophulariaes, 3 Fructus Lycii 6,6 Radix Ophiopogonis
Semen Coicis 6 Radix Glycyrrhizaes 2 Fructus Crataegis 6 Fructus Jujubaes 6.
Described medicament can be a said peroral dosage form on any pharmaceutics, as decoction, pill, powder, medicated wine, taste unguentum and distillate medicinal water etc.
Described Herba Dendrobii also can be with replacements such as the Dendrobium nobile of equal genus, Dendrobium Moniliformes, and described Radix Panacis Quinquefolii can be with the ginseng medicine thing as not directly replacements such as ginseng (Korean Ginseng), Radix Ginseng Rubra, Radix Ginseng.
Described Ramulus et folium taxi cuspidatae is branch, leaf, stem, root and the bark of Semen Phaseoli Lignum seu Ramulus Cunninghamiae Lanceolatae.
Described medicament can make with conventional method.
As processing decoction: place rustless steel to decoct container (after wherein Ramulus et folium taxi cuspidatae is cleaned, dries, pulverizes confected materials with following decocting method, pack with filter paper bag), about 10 times by medicine weight add cold water for the first time, soak after 30 minutes, decoct with conventional decocting method that drop goes out after about 30 minutes; Decoct in the container at rustless steel then and add 6 times of by crude drug weight water for the second time, decoct with the decocting method of routine that drop goes out after about 25 minutes.Twice fried medicine juice, lump together filtration, packing then, by 180 milliliters every bag packing specification, one day dosage is two bags.
Decoction also can be processed by the following method: material medicine is poured in the filter bag, placing rustless steel decocts in the container, press 15 heavy cold water extraordinarily of crude drug, soak after 30 minutes, decoct about 50 minutes after-filtration, pack with the decocting method of routine, by 180 milliliters every bag packing specification, one day dosage is two bags.
Compared with prior art, the invention has the advantages that and utilize traditional Chinese medicine theory, with the strengthening vital QI to eliminate pathogenic factors is principle, extensively adopt tonification gas the moon, anticancer method for detoxification, especially at most of malignant tumor patient underwent operative and radiotherapy, after the chemotherapy, existing the cloudy serious consumption of gas hinders, the surplus heresy of cancer poison is not to the greatest extent, the higher pathological state of dangerous probability of recurrence and cancer cell metastasis, adopt the mutual compatibility of said medicine, have the good anticancer detoxicating functions, and have less toxic and side effects, event is suitable for tumour patients, especially postoperative or puts, it after the chemotherapy best treatment period.
The principal agent Ramulus et folium taxi cuspidatae is a kind of newfound anticancer herbal drug, proves through pharmacological evaluation, and paclitaxel active anticancer contained in this product is the strongest, and multiple cancers such as breast carcinoma, carcinoma of endometrium, pulmonary carcinoma are had therapeutical effect; Semen Coicis function invigorating spleen and reinforcing stomach, modern study confirm that again it has antitumaous effect; Herb Gynostemmae Pentaphylli can benefiting QI and nourishing blood, heat-clearing and toxic substances removing, and the eliminating mass knot clinically is usually used in treating disease such as tumor.More than three medicines cooperate, anticancer effect brings out the best in each other.Radix Panacis Quinquefolii has QI invigorating the moon, clear asthenic fire, and the effect of promoting the production of body fluid to quench thirst is the panacea of strengthening the body resistance, " Records of Tradition Chinese and Western Medicine in Combination " calls it: " can subsidize edema caused by disorder of QI, and energy tonification blood system "; Radix Astragali function benefiting QI for strengthening the superficies, the tonifying the lung spleen invigorating, " herbal classic is met former " claims its " all void of energy tonifying five ZANG-organs "; The Fructus Lycii tonifying liver nourishes blood, and is longer than the replenishing essence kidney tonifying especially; Herba Dendrobii is the outstanding person in the Herba Dendrobii kind, and merit is arrogated to oneself the stomach reinforcing that promotes the production of body fluid, and clearing away heat and nourishing YIN has the laudatory title of " Herba mesonae chinensis "; Radix Ophiopogonis nourishing YIN and moistening the lung, reinforcing stomach reg fluid, " book on Chinese herbal medicine justice " claim its " specially mending stomach-Yin, grow body fluid, is product on the sweet benefit of building up one's health by taking tonic "; The merit of Radix Scrophulariae nourishing YIN to lower pathogenic fire is outstanding especially, and antipyretic and antidote functions is arranged; Fructus Crataegi can stagnate by removing food stagnancy, dissipating blood stasis blood, the kind lump in the abdomen of controlling; Fructus Jujubae is taken a tonic or nourishing food to build up one's health taste, QI invigorating and blood producing; The Radix Glycyrrhizae heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription.
Radix Panacis Quinquefolii can be with the ginseng medicine thing as not directly replacements such as ginseng (Korean Ginseng), Radix Ginseng Rubra, Radix Ginseng, the composition of these medicines all contains the ginsenoside, and the general character of its effect is a tonification vigour, strengthening the body resistance, and Radix Panacis Quinquefolii is cooler in the nature, and is variant slightly on drug effect with above-listed ginseng medicine thing; Herba Dendrobii is various in style, and Herba Dendrobii can be with the plant such as the replacements such as Dendrobium nobile, Dendrobium Moniliforme of equal genus, and the general character of these medicines is all to have clearing away heat and nourishing YIN, the effect of promoting the production of body fluid to quench thirst.
Zoopery shows that the compound taxol tumour inhibiting rate is higher than the Ramulus et folium taxi cuspidatae group, and safety testing compound taxol toxic action can not be measured LD
50Its maximum tolerated dose is 137.7 times of the clinical consumption of adult.
Drug effect and experimentation
1. compound taxol is to S
180Tumor-bearing mice inhibition test such as table 1:
Table 1 the present invention is to sarcoma S
180The tumor-inhibiting action of tumor-bearing mice (X+S)
| The Mus number | Tumor heavy (g) | Tumour inhibiting rate (%) | The P value | |
| Matched group Ramulus et folium taxi cuspidatae group compound taxol group | ????9 ????9 ????9 | ????4.35±1.06 ????3.23±0.72 ????1.84±0.75 | ? ????28.9 ????59.6 | ? ????＞0.05 ????＜0.05 |
Conclusion:
Compound taxol group and Ramulus et folium taxi cuspidatae group are to sarcoma S
180Tumor-bearing mice tumor body all has certain tumor-inhibiting action, and the compound taxol group is the most obvious, P＜0.05.
2. safety experiment:
Ramulus et folium taxi cuspidatae acute toxicity test report:
Add up through NDST software Bliss ' s
LD
5=99.654 (g/kg) scope 79.6326～124.7092 is equivalent to 43 times of clinical consumption
LD
50=153.344 ± 16.803 (g/kg) are equivalent to 66.4 ± 7.3 times of clinical consumption
LD
95=235.9605 (g/kg) scope 178.3～312.2 is equivalent to 102 times of clinical consumption
Maximum tolerated dose of the present invention is equivalent to more than 137.77 times of clinical consumption of being grown up
3. increase in life span sees Table 2
Table 2 the present invention is to the influence of increase in life span
| Group | Average survival natural law (my god) | Increase in life span 1% |
| Ramulus et folium taxi cuspidatae group compound taxol (the present invention) group matched group | 16.2±5.32 20.77±3.48 14.42±4.12 | ??12.34 ??44.06 ??- |
* and model control group are than P＜0.05**
Clinical research
The Inst. of Traditional Chinese Medicine, Zhejiang Prov and the east of a river, the Ningbo people pacify the treatment and prevention of tumour institute and use the present invention, and adopting Ramulus et folium taxi cuspidatae is herbal mixture decoct treatment malignant tumor 106 examples of principal agent, obtains satisfactory effect, now is reported as follows.
1, this group of physical data case all belongs to advanced malignant tumor, and wherein patient's 82 examples behind postoperative or the chemoradiotherapy are not suitable for operation or refusal operation and postoperative recurrence and transfer case 24 examples, but clinical observation index is arranged, and all confirm through pathology or cytology.In 106 examples, male 62 examples, women 44 examples, 38～78 years old age, The median age 52 years old.Karnofsky integration (KPS) 〉=40 minute.Tumor kind: pulmonary carcinoma 12 examples, male 9 examples, women 3 examples; Colorectal cancer 28 examples, male 19 examples, women 9 examples; Gastric cancer 22 examples, male 16 examples, women 6 examples; Breast carcinoma 25 examples are the women; Carcinoma of prostate 15 examples are the male; Cancer of biliary duct 4 examples, male 3 examples, women 1 example.Histological type: lung squamous cancer 2 examples, adenocarcinoma 8 examples, adenosquamous carcinoma 1 example, small cell undifferentiated carcinoma 1 example.Rectal cancer 14 examples (tubular adenocarcinoma 9 examples, mucinous adenocarcinoma 5 examples); Colon cancer 14 examples (mucinous adenocarcinoma 5 examples, papillary adenocarcinoma 9 examples); Gastric cancer 22 examples (mucinous adenocarcinoma 14 examples, poorly differentiated adenocarcinoma and each 4 example of seal floss cell carcinoma).(UICC in 1997) by stages by stages for TNM: pulmonary carcinoma II phases 2 example, IIIA phases 4 example, IIIB phases 2 example, IV phases 4 example.Colorectal cancer Dukes ' C1 phases 8 example, Dukes ' C2 phases 12 example, Dukes ' D phases 8 example.Gastric cancer IIIB phases 17 example, IV phases 5 example.Breast carcinoma II phases 5 example, III phases 18 example, IV phases 2 example.Carcinoma of prostate III phases 5 example, IV phases 10 example.Cancer of biliary duct III phases 3 example, IV phase 1 example.Transfer case: superficial lymph is carried down and is moved 8 examples, and wherein the pulmonary carcinoma supraclavicular lymph nodes shifts 1 example, lymph nodal metastasis 4 examples, rectal cancer inguinal lymph nodes and shifts 3 examples.In the pulmonary carcinoma companion lung, mediastinum, pleura shift 1 example, pulmonary carcinoma hepatic metastases 1 example, colorectal cancer with liver metastases 1 example, carcinoma of prostate hepatic metastases 1 example, cancer of biliary duct hepatic metastases 1 example, breast carcinoma hepatic metastases 1 example.Bone metastases of lung cancer 1 example, the colorectal cancer bone shifts 1 example, breast carcinoma bone transferase 12 example, the carcinoma of prostate bone shifts 1 example.Gastric cancer posterior peritoneum lymphatic metastasis companion pancreas soaks into 1 example, cancer of biliary duct posterior peritoneum lymphatic metastasis 1 example.The carcinoma of prostate lung shifts 1 example, and the colorectal cancer lung shifts 1 example, and the carcinoma of prostate vertigo moves 1 example.
2, Therapeutic Method compound taxol (the present invention) decoction serve on 30 days for one-period, and with 2～3 cycles, drug withdrawal is after 10～20 days, medication again, average 6.3 cycles.
3, observation index treatment before and after look three is big conventional, Liver and kidney merit, electrocardiogram, Abdominal B type ultrasonography, Chest X-rays or rabat, CT etc.Have a blood test weekly in the therapeutic process conventional 1 time, itemized record KPS, body weight, symptom and sign change and each system's toxicity.The treatment effective percentage adopts the objective curative effect index evaluation of WHO solid tumor, and toxicity adopts WHO toxicity grading standard.Estimate recent clinical efficacy, take this preparation 2-3 at least more than the cycle.
4, statistical method adopts x2 and t check.
5, result
5.1 clinical efficacy sees Table 3.
The clinical short term effect of table 3 (%)
| The sick kind | The example number | ????CR | ????PR | ????NC | ????PD | ??CR+PR | The meta catabasis (moon) | Median survival interval (moon) |
| Pulmonary carcinoma | ??12 | ????1 | ????2 | ????5 | ????4 | ??3(25.00) | ????5.6 | ??8.1(4～36) |
| Colorectal cancer | ??28 | ????4 | ????8 | ????8 | ????8 | ??12(42.86) | ????5 | ??12.5(6～24) |
| Gastric cancer | ??22 | ????4 | ????6 | ????5 | ????7 | ??10(45.46) | ????4.8 | ??8.3(3.1～19) |
| Breast carcinoma | ??25 | ????3 | ????9 | ????4 | ????9 | ??12(48.00) | ????10.8 | ??15(8～36) |
| Carcinoma of prostate | ??15 | ????0 | ????4 | ????7 | ????4 | ??4(26.67) | ????12.4 | ??15(3～36) |
| Cancer of biliary duct | ??4 | ????0 | ????2 | ????1 | ????1 | ??2(50) | ????6 | ??12(9～36) |
| Add up to | ??106 | ????12(11.32) | ????31(29.25) | ????30(28.30) | ????33(31.13) | ??43(40.57) | ????7.4 | ??11.81(3～36) |
5.2 KPS is average 62 minutes before the full group treatment of quality of life, average 85 minutes of treatment back.The KPS raising accounted for to account in 6.38%, 30 minute to account in 10.64%, 20 minute and accounted for 70.21% in 12.77%, 10 minute in 40 minutes.Weight increase 64.15%.
5.3 toxicity sees Table 4.As known from Table 4, toxicity does not have 1 routine II～IV degree generation; Only be the untoward reaction of minority I degree, main performance is felt sick, vomiting, appetite decline, leukopenia and abnormal liver function, continues treatment but all do not influence.
Table 4 toxicity
6, discuss
The Ramulus et folium taxi cuspidatae main active is paclitaxel, Ba Kating-III, RO, Rb1, Rg1 and triterpenoid saponin etc.Active anticancer is the strongest, and the microtubule of mechanism of action and target site united state promotes the microtubule assembling, suppresses its depolymerization, thereby suppress the Spindle function cell mitogen is stagnated.Found that up to now paclitaxel can induce the apoptosis of kinds of tumors, comprised ovarian cancer, lymphoma, leukemia, pulmonary carcinoma, gastrointestinal cancer and breast carcinoma etc., RESEARCH ON CELL-BIOLOGY finds that the taxol induced cell mitogen is stagnated the G2-M phase that betides.Report paclitaxels such as Bhalla can make the bcl-2MRNA downward modulation.The bcl-2 phosphorylation of taxol induced is only and causes more major reason of tumor death.Use the present invention, adopt Ramulus et folium taxi cuspidatae compound prescription decoctum treatment kinds of tumors, effective percentage (CR+PR): pulmonary carcinoma 25.00%, colorectal cancer 42.86%, gastric cancer 45.46%, breast carcinoma 48%, carcinoma of prostate 26.67%, cancer of biliary duct 50%.This group total effective rate is 40.57%.7.4 months meta catabasises, median survival interval 11.81 months.Patient KPS obviously improves, weight increase 64.15%, and this may be relevant with the multiplicity effect of Chinese medicine of the present invention.Studies show that both at home and abroad it is the main dose-limiting toxicity of paclitaxel that neutrophilic granulocyte reduces, all the other common untoward reaction are alopecia, muscular soreness, peripheral neuropathy, digestive tract reaction and acute anaphylactic reaction etc.Usually need with the support of G-CSF/GM-CSF class medicine and adopt Polyglucan medicine (dexamethasone, diphenhydramine, cimetidine/ranitidine) in advance.Oral Ramulus et folium taxi cuspidatae compound preparation is used in this research, does not adopt above-mentioned processing, does not have 1 routine II～IV degree toxicity and takes place, and only has that the minority case I degree leukopenia takes place, is felt sick, vomiting, appetite descends and liver function (AST) changes.This may be on the one hand activity, time, oral absorption mode process are relevant in vivo with the dosage form of medicine, route of administration, medicine.Ramulus et folium taxi cuspidatae is equipped with Chinese medicine and forms compound prescription decoctum on the other hand, has the Chinese medicine characteristic really: anticancer, as to press down cancer and human body immunity improving function multiple action, effects such as eliminating pathogenic factor for supporting vital QI, activating collaterals and eliminating stagnation are worth clinical application.
The specific embodiment
Below in conjunction with embodiment the present invention is described in further detail.
Embodiment one: take by weighing one day raw material of a people (gram) by following proportioning:
Ramulus et folium taxi cuspidatae 800 Radix Panacis Quinquefoliis 100 Herb Gynostemmae Pentaphylli 400 Herba Dendrobii 100
The Radix Astragali 600 Radix Scrophulariaes, 300 Fructus Lycii 600,600 Radix Ophiopogonis
Semen Coicis 600 Radix Glycyrrhizaes 200 Fructus Crataegis 600 Fructus Jujubaes 600
Process by the following method: place rustless steel to decoct container (after wherein Ramulus et folium taxi cuspidatae is cleaned, dries, pulverizes, packing) confected materials, add 55 kilograms in cold water, soaks after 30 minutes with filter paper bag, with the decocting method decoction of routine after 25 minutes drop go out; In rustless steel decocts container, add 33 kilograms in water then, with conventional decocting method decoction after 20 minutes drop go out.Twice fried medicine juice, lump together filtration, packing then, by 180 milliliters every bag packing specification, totally 200 bags, one day dosage is two bags.
Embodiment two: take by weighing raw material (gram) by following proportioning
Ramulus et folium taxi cuspidatae 5600 Radix Panacis Quinquefoliis 700 Herb Gynostemmae Pentaphylli 2800 Herba Dendrobii 700
The Radix Astragali 4200 Radix Scrophulariaes, 2100 Fructus Lycii 4200,4200 Radix Ophiopogonis
Semen Coicis 4200 Radix Glycyrrhizaes 1400 Fructus Crataegis 4200 Fructus Jujubaes 4200
Process by the following method: material medicine is poured in the filter bag, placing rustless steel decocts in the container, add 580 kilograms in cold water, soak after 30 minutes, decoct about 50 minutes after-filtration, pack with the decocting method of routine, by 180 milliliters every bag packing specification, totally 1400 bags, one day dosage is two bags.
Embodiment three: take by weighing raw material (kilogram) by following proportioning
Ramulus et folium taxi cuspidatae 6 Radix Panacis Quinquefoliis 0.5 Herb Gynostemmae Pentaphylli 2 Herba Dendrobii 0.5
The Radix Astragali 4 Radix Scrophulariaes, 1.5 Fructus Lycii 4,4 Radix Ophiopogonis
Semen Coicis 4 Radix Glycyrrhizaes 1 Fructus Crataegi 4 Fructus Jujubaes 4
Embodiment four: take by weighing raw material (kilogram) by following proportioning
Ramulus et folium taxi cuspidatae 7 Radix Panacis Quinquefoliis 0.8 Herb Gynostemmae Pentaphylli 3 Herba Dendrobii 0.7
The Radix Astragali 5 Radix Scrophulariaes, 2.2 Fructus Lycii 5,5 Radix Ophiopogonis
Semen Coicis 5 Radix Glycyrrhizaes 1.5 Fructus Crataegis 5 Fructus Jujubaes 5
In the foregoing description, Herba Dendrobii can be with replacements such as the Dendrobium nobile of equal genus, Dendrobium Moniliformes, and Radix Panacis Quinquefolii can be with the ginseng medicine thing as not directly replacements such as ginseng (Korean Ginseng), Radix Ginseng Rubra, Radix Ginseng.
Claims (8)
1, a kind of anticancer taxad medicine is characterized in that it is the medicament of being made by the following weight proportion raw material
4～6 Radix Ophiopogonis 4～6 of Ramulus et folium taxi cuspidatae 6～8 Herb Gynostemmae Pentaphylli 2～4 Radixs Astragali
Radix Scrophulariae 1.5～3 Fructus Lycii 4～6 Semen Coiciss 4～6 Radix Glycyrrhizaes 1～2
Fructus Crataegi 4～6 Fructus Jujubaes 4～6 Dendrobium medicines 0.5～1 ginseng medicine 0.5～1.
2, a kind of anticancer taxad medicine as claimed in claim 1 is characterized in that the weight proportion of each raw material is
4～6 Radix Ophiopogonis 4～6 of Ramulus et folium taxi cuspidatae 6～8 Herb Gynostemmae Pentaphylli 2～4 Radixs Astragali
Radix Scrophulariae 1.5～3 Fructus Lycii 4～6 Semen Coiciss 4～6 Radix Glycyrrhizaes 1～2
Fructus Crataegi 4～6 Fructus Jujubaes 4～6 Herba Dendrobii 0.5～1 Radix Panacis Quinquefolii 0.5～1.
3, a kind of anticancer taxad medicine as claimed in claim 1 is characterized in that the weight proportion of each raw material is
6 Radix Ophiopogonis 6 of Ramulus et folium taxi cuspidatae 8 Herb Gynostemmae Pentaphylli 4 Radixs Astragali
Radix Scrophulariae 3 Fructus Lycii 6 Semen Coiciss 6 Radix Glycyrrhizaes 2
Fructus Crataegi 6 Fructus Jujubaes 6 Herba Dendrobii 1 Radix Panacis Quinquefolii 1.
4,, it is characterized in that described medicament is a said peroral dosage form on any pharmaceutics as claim 1 or 2 or 3 described a kind of anticancer taxad medicines.
5, a kind of anticancer taxad medicine as claimed in claim 4 is characterized in that described medicament is a decoction.
6, a kind of anticancer taxad medicine as claimed in claim 1 is characterized in that described Ramulus et folium taxi cuspidatae is branch, leaf, stem, root and the bark of Semen Phaseoli Lignum seu Ramulus Cunninghamiae Lanceolatae.
7, a kind of anticancer taxad medicine as claimed in claim 4 is characterized in that described medicament makes with conventional method.
8, a kind of anticancer taxad medicine as claimed in claim 5 is characterized in that described decoction makes with conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100498535A CN100428949C (en) | 2005-05-27 | 2005-05-27 | Anticancer taxad Chinese medicine prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100498535A CN100428949C (en) | 2005-05-27 | 2005-05-27 | Anticancer taxad Chinese medicine prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1706473A true CN1706473A (en) | 2005-12-14 |
| CN100428949C CN100428949C (en) | 2008-10-29 |
Family
ID=35580705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100498535A Expired - Fee Related CN100428949C (en) | 2005-05-27 | 2005-05-27 | Anticancer taxad Chinese medicine prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100428949C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448375C (en) * | 2006-09-30 | 2009-01-07 | 广西中医学院制药厂 | Health-care food for immunity regulating and antifatigue and its production method |
| CN101342203B (en) * | 2008-08-26 | 2011-12-07 | 南京中医药大学 | Anti-cancer medicine compound lychee formulation and preparation method thereof |
| CN102935097A (en) * | 2011-12-19 | 2013-02-20 | 徐英奎 | Taxus compound traditional Chinese medicine having anticancer effect and preparation method thereof |
| CN104173950A (en) * | 2014-09-15 | 2014-12-03 | 程惠华 | Chinese herbal medicine composition for treating prostatic cancer |
| CN104547106A (en) * | 2015-01-16 | 2015-04-29 | 任永 | Pharmaceutical composition for treating cancers |
| CN104666671A (en) * | 2015-01-22 | 2015-06-03 | 林树芳 | Anti-cancer analgesic medicine of Chinese yew and preparation method of anti-cancer analgesic medicine |
| CN104757211A (en) * | 2015-04-14 | 2015-07-08 | 深圳锦霞红豆杉生态健康股份有限公司 | Taxus chinensis breast enlargement adenocarcinoma-resisting tea and preparation method thereof |
| CN104971317A (en) * | 2015-07-22 | 2015-10-14 | 陈荣友 | Traditional Chinese medicine for treating tumors |
| CN105647754A (en) * | 2014-12-15 | 2016-06-08 | 仁怀市益康红豆杉专业合作社 | Preparation method of compound Chinese yew wine |
| CN114306580A (en) * | 2021-04-22 | 2022-04-12 | 庞作仁 | Method and process for preparing compound paclitaxel anti-leukemia capsule tablet |
| CN116172189A (en) * | 2022-10-13 | 2023-05-30 | 袁朝阳 | Cell nutrition diet composition for treating cancer and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391942A (en) * | 2002-08-20 | 2003-01-22 | 韩松 | New medicine for anti-cancer, anti-AIDs and giving-up drug habits and its preparing and applying method |
-
2005
- 2005-05-27 CN CNB2005100498535A patent/CN100428949C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448375C (en) * | 2006-09-30 | 2009-01-07 | 广西中医学院制药厂 | Health-care food for immunity regulating and antifatigue and its production method |
| CN101342203B (en) * | 2008-08-26 | 2011-12-07 | 南京中医药大学 | Anti-cancer medicine compound lychee formulation and preparation method thereof |
| CN102935097A (en) * | 2011-12-19 | 2013-02-20 | 徐英奎 | Taxus compound traditional Chinese medicine having anticancer effect and preparation method thereof |
| CN104173950A (en) * | 2014-09-15 | 2014-12-03 | 程惠华 | Chinese herbal medicine composition for treating prostatic cancer |
| CN104173950B (en) * | 2014-09-15 | 2017-03-15 | 程惠华 | A kind of herbal composite for treating prostate cancer |
| CN105647754A (en) * | 2014-12-15 | 2016-06-08 | 仁怀市益康红豆杉专业合作社 | Preparation method of compound Chinese yew wine |
| CN104547106A (en) * | 2015-01-16 | 2015-04-29 | 任永 | Pharmaceutical composition for treating cancers |
| CN104666671A (en) * | 2015-01-22 | 2015-06-03 | 林树芳 | Anti-cancer analgesic medicine of Chinese yew and preparation method of anti-cancer analgesic medicine |
| CN104757211A (en) * | 2015-04-14 | 2015-07-08 | 深圳锦霞红豆杉生态健康股份有限公司 | Taxus chinensis breast enlargement adenocarcinoma-resisting tea and preparation method thereof |
| CN104971317A (en) * | 2015-07-22 | 2015-10-14 | 陈荣友 | Traditional Chinese medicine for treating tumors |
| CN114306580A (en) * | 2021-04-22 | 2022-04-12 | 庞作仁 | Method and process for preparing compound paclitaxel anti-leukemia capsule tablet |
| CN116172189A (en) * | 2022-10-13 | 2023-05-30 | 袁朝阳 | Cell nutrition diet composition for treating cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100428949C (en) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100428949C (en) | Anticancer taxad Chinese medicine prepn | |
| CN101264311B (en) | Natural pharmaceutical composition, its preparation and its attenuation synergistic use in cancer radiotherapy and chemotherapy | |
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN101716318B (en) | Traditional Chinese medicine preparation for treating tumor of digestive system | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103948689A (en) | Medicinal composition for treating non-small cell lung cancer and application thereof | |
| CN107468747A (en) | A kind of ginseng composition for being advantageous to anticancer, anti-cancer and preparation method thereof | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN103585546A (en) | Application of traditional Chinese medicine composition to preparation of drugs for treating diarrhea caused by cancer chemotherapy | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN105663728A (en) | Traditional Chinese medicine compound preparation for treating colorectal cancer and preparation method thereof | |
| CN105126030A (en) | Zhuang medicine composition assisted in resisting lung cancer | |
| CN101049464A (en) | Preparation of Chinese traditional medicine in use for tumor, and preparation method | |
| CN101120977A (en) | Medicine for treating tumor | |
| CN105596890A (en) | Method for preparing traditional Chinese medicine composition for treating lung cancer | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN1836702A (en) | Medicine for treating tumour and its preparing method | |
| CN101530589B (en) | Chinese medicinal preparation for treating cancers | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN100348249C (en) | Method for preparing medicine for treating malignancy disease and use thereof | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN107281212B (en) | A kind of jujube complex polysaccharide composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081029 Termination date: 20180527 |